Clinical Trial Update: TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TT-10 and TT-4 (Portage Biotech) exploring single-agent and combination therapy in advanced solid tumors, with recruitment ongoing in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Colorectal Cancer
• Endometrial Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Renal Cell Carcinoma

Drugs mentioned

• TT-10
• TT-4

Snippet

Sponsor: Portage Biotech | Conditions: Renal Cell Cancer, Castrate Resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING